You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Dow
Moodys
Baxter
McKinsey

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Patent: 4,985,360

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,985,360
Title: Novel bilirubin oxidase which has a substrate specifity to bilirubin, but not to biliverdin, catechol and hemin
Abstract:A novel bilirubin oxidase is provided having a substrate specificity for bilirubin but not to, at least, biliverdin, catechol and hemin and which catalyzes the enzyme reaction between two moles of bilirubin and one mole of oxygen to yield two moles of biliverdin and two moles of water. A process is also provided for the production of said novel bilirubin oxidase, which comprises cultivating a bilirubin oxidase-producing fungus of the genus Penicillium in a culture medium and collecting the bilirubin oxidase from the culture mixture. A method of determining the content of bilirubin in a sample to be analyzed is further provided which comprises contacting the sample with the bilirubin oxidase to convert bilirubin in the sample into biliverdin and determining the amount of biliverdin formed or the amount of oxygen consumed therefor, as well as a method for removing bilirubin contained in a sample to be analyzed, which comprises contacting the sample with said novel bilirubin oxidase.
Inventor(s): Takahashi; Mamoru (Shizuoka, JP), Imamura; Shigeyuki (Shizuoka, JP), Takada; Masaki (Shizuoka, JP)
Assignee: Toyo Jozo Kabushiki Kaisha (Shizuoka, JP)
Application Number:07/204,868
Patent Claims:see list of patent claims

Details for Patent 4,985,360

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Recordati Rare Diseases, Inc. PANHEMATIN hemin POWDER, FOR SOLUTION 101246 1 1983-07-20   Start Trial Toyo Jozo Kabushiki Kaisha (Shizuoka, JP) 2008-01-15 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Colorcon
Medtronic
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.